Modular Medical, INC 8-K filings

Modular Medical, Inc. announced the pricing of a registered direct offering of 750,000 shares of common stock, raising approximately $3.4 million.

Modular Medical, Inc. has officially regained compliance with the Nasdaq minimum bid price requirement after maintaining a share price above $1.00 for 10 consecutive trading days.

Modular Medical, Inc. announced a 1-for-30 reverse stock split to maintain its Nasdaq listing, effective March 31, 2026.

Modular Medical, Inc. announced a significant workforce reduction impacting 29% of its employees to decrease operating expenses and cash burn.

Modular Medical, Inc. announced the successful pricing and closing of a $12 million public offering of common stock and warrants.

Modular Medical, Inc. has secured a $350,000 revolving credit facility from its CEO, James E. Besser, due March 25, 2026, at a 12% interest rate.

Modular Medical, Inc. shareholders approved an increase in authorized common stock and granted the board discretion to effect a reverse stock split at its annual meeting on January 23, 2026.

Modular Medical, Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum $1 bid price requirement, pushing the deadline to June 29, 2026.

Modular Medical, an insulin delivery technology company, announced the pricing of a $4.68 million public offering of common stock and accompanying warrants to fund operations and working capital.

Modular Medical, Inc. announced it will receive approximately $3.7 million in gross proceeds by inducing holders of existing warrants to exercise at a reduced price, issuing new warrants in return.

Modular Medical, Inc. received a notice from Nasdaq indicating non-compliance with the minimum $1 bid price requirement, initiating a 180-day period to regain compliance.

Modular Medical, an insulin delivery technology company, has appointed experienced healthcare and medical device executive Jeff Goldberg to its Board of Directors, effective May 22, 2025.

Modular Medical secures $12.5 million through private placements to advance its MODD1 product and FDA submission for a tubeless version.

Modular Medical's 2025 annual meeting resulted in the election of directors, approval of an equity incentive plan amendment, and ratification of the company's independent auditor.

Modular Medical, Inc. successfully closed a public offering of common stock, generating approximately $8.2 million in gross proceeds.

Modular Medical has received FDA clearance for its MODD1 insulin pump, designed to be more accessible and affordable, with commercial availability expected in early 2025.

Modular Medical cancels milestone-based stock options for executives due to an FDA clearance delay and issues new options tied to a revised deadline.

Modular Medical has increased the base salaries of its Chairman/President/CFO and COO, and granted them stock options, effective April 1, 2024.

Modular Medical has entered into an underwriting agreement for a public offering of 9,090,910 shares of common stock at $1.10 per share, with an option for the underwriter to purchase additional shares.

Modular Medical increased its authorized shares of common stock from 50 million to 100 million and held its annual shareholder meeting.

Modular Medical has submitted its MODD1 next-generation insulin pump to the FDA for 510(k) clearance, marking a significant step towards launching its user-friendly and affordable insulin delivery technology.